Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02V-adjuvanted hepatitis B vaccine

Kidney International

Volumn 77, Issue 3, 2010, Pages 247-255

  Surquin, Murielle ^a,k   Tielemans, Christian L ^b,l   Kulcsár, Imre ^c   Ryba, Miroslav ^d   Vörös, Péter ^e   Mat, Olivier ^f   Treille, Serge ^g   Dhaene, Michel ^h   Stolear, Jean Claude ⁱ   Kuriyakose, Sherine O ^j   Leyssen, Maarten X ^j   Houard, Sophie A ^a  

^a Henogen SA   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c Markusovszky Teaching Hospital   (Hungary)

^d REGIONAL HOSPITAL LIBEREC   (Czech Republic)

^e Szent Istvan Hospital   (Hungary)

^f Service de Dialyse   (Belgium)

^g Hospital Civil Charleroi   (Belgium)

^h Clinique Louis Caty   (Belgium)

ⁱ Service de Nephrologie   (Belgium)

^j GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^k BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^l UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

more..

Author keywords

Adjuvant; HB AS02 vaccine; HB AS04 vaccine; Hemodialysis; Hepatitis B; Vaccination

Indexed keywords

ALUMINUM PHOSPHATE; ANTIBODY; HB AS02; HB AS04; HEPATITIS B VACCINE; PHOSPHORYL LIPID A; UNCLASSIFIED DRUG; WATER OIL CREAM;

ADJUVANT THERAPY; ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FRACTURE; GASTROINTESTINAL SYMPTOM; GEOMETRY; HEADACHE; HEMATOMA; HEMODIALYSIS PATIENT; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; IMMUNITY; IMMUNOGENICITY; INFECTION; INJECTION SITE PAIN; INJECTION SITE SWELLING; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PERITONEAL DIALYSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 74449084299     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.454     Document Type: Article

References (36)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
2. World Health Organization (WHO). Hepatitis B. Fact sheet N1204. Revised August 2008. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/ Accessed September 2009.
3. Wong PN, Fung TT, Mak SK et al. Hepatitis B virus infection in dialysis patients. J Gastroenterol Hepatol 2005; 20: 1641-1651.
4. Centers for Disease Control and Prevention (CDC). Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001; 50: 1-43.
5. Advisory Committee on Immunization Practices (ACIP). Guidelines for vaccinating kidney dialysis patients and patients with chronic kidney disease. June 2006. Available at: http://www.cdc.gov/vaccines/pubs/downloads/b-dialysis- guide.pdf Accessed September 2009.
6. American Society of Transplantation. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2004; 4(Suppl 10): 160-163.
7. Peces R, Laurés AS. Persistence of immunologic memory in long-term hemodialysis patients and healthcare workers given hepatitis B vaccine: role of a booster dose on antibody response. Nephron 2001; 89: 172-176.
8. Bel'eed K, Wright M, Eadington D et al. Vaccination against hepatitis B infection in patients with end stage renal disease. Postgrad Med J 2002; 78: 538-540.
9. DaRoza G, Lowen A, Djurdjev O et al. Stages of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kid Dis 2003; 42: 1184-1192.
10. Bruguera M, Rodicio JL, Alcazar JM et al. Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients. Vaccine 1990; 8(Suppl): S47-S49.
11. Liu YL, Kao MT, Huang CC. A comparison of responsiveness to hepatitis B vaccination in patients on hemodialysis and peritoneal dialysis. Vaccine 2005; 23: 3957-3960.
12. European Medicines Agency (EMEA). European Public Assessment Reports (EPARs) for authorized medicinal products for human use. Fendrix. EPAR H-C-50. Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/fendrix/fendrix. htm Accessed September 2009.
13. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007; 6: 723-739.
14. Kong NCT, Beran J, Kee SA et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005; 68: 2298-2303. (Pubitemid 43117807)
15. Kong NCT, Beran J, Kee SA et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int 2008; 73: 856-862.
16. Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 2007; 6: 133-140.
17. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-hemodialysis and hemodialysis patients. Expert Opin Biol Ther 2008; 8: 235-247.
18. Vandepapelière P, Horsmans Y, Moris P et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008; 26: 1375-1386.
19. Fabrizi F, Martin P. Hepatitis B virus infection in dialysis patients. Am J Nephrol 2000; 20: 1-11.
20. Burdick RA, Bragg-Gresham JL, Woods JD et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2003; 63: 2222-2229.
21. Jilg W, Schmidt M, Deinhardt F et al. Hepatitis B vaccination: how long does protection last? Lancet 1984; ii: 458.
22. Jilg W, Schmidt M, Deinhardt F. Persistence of specific antibodies after hepatitis B vaccination. J Hepatol 1988; 6: 201-207.
23. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355: 561-565.
24. Sezer S, Ozdemir FN, Güz G et al. Factors influencing response to hepatitis B virus vaccination in hemodialysis patients. Transplant Proc 2000; 32: 607-608.
25. Ramezani A, Velayati AA, Eslamifar A et al. Persistence of hepatitis B vaccine immunity in hemodialysis patients. Ther Apher Dial 2008; 12: 143-146.
26. Ramezani A, Eslamifar A, Banifazl M et al. Efficacy and long-term immunogenicity of hepatitis B vaccine in haemodialysis patients. Int J Clin Pract 2009; 63: 394-397.
27. Salisbury DM, Begg NT. Immunisation Against Infectious Diseases. HM Stationary Office: London, 1996, pp 95-108.
28. Impfempfehlungen der ständigen impfkommission (STIKO) an RKI. Epidemiogisches Bulletin No. 2. Robert Koch Institut: Berlin, 2000.
29. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005; 11(4 Suppl): S63-S68.
30. Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol 1995; 6: 495-524.
31. Evans JT, Cluff CW, Johnson DA et al. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2003; 2: 219-229.
32. Verkade MA, van de Wetering J, Klepper M et al. Peripheral blood dendritic cells and GM-CSF as an adjuvant for hepatitis B vaccination in hemodialysis patients. Kidney Int 2004; 66: 614-621.
33. Hesselink DA, Betjes MG, Verkade MA et al. The effects of chronic kidney disease and renal replacement therapy on circulating dendritic cells. Nephrol Dial Transplant 2005; 20: 1868-1873.
34. Lim WH, Kireta S, Russ GR et al. Uremia impairs blood dendritic cell function in hemodialysis patients. Kidney Int 2007; 71: 1122-1131.
35. Verkade MA, van Druningen CJ, Op de Hoek CT et al. Decreased antigen-specific T-cell proliferation by moDC among hepatitis B vaccine non-responders on haemodialysis. Clin Exp Med 2007; 7: 65-71.
36. Bojang KA. RTS,S/AS02A for malaria. Expert Rev Vaccines 2006; 5: 611-615.